The translocator protein (TSPO), previously known as the peripheral benzodiazepine receptor, is of longstanding medical interest as both a biomarker for neuroinjury and a potential drug target for neuroinflammation and other disorders. Recently it was shown that ligand residence time is a key factor determining steroidogenic efficacy of TSPO-binding compounds. This spurs interest in simulations of (un)binding pathways of TSPO ligands, which could reveal the molecular interactions governing ligand residence time. In this study, we use a weighted ensemble algorithm to determine the unbinding pathway for different poses of PK-11195, a TSPO ligand used in neuroimaging. In contrast with previous studies, our results show that PK-11195 does not dissociate directly into solvent but instead dissociates via the lipid membrane by going between the transmembrane helices. We analyze this path ensemble in detail, constructing descriptors that can facilitate a general understanding of membrane-mediated ligand binding.
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The binding affinity of a ligand to its protein target has long been viewed as the key parameter determining its efficacy. However, recent studies have shown that in some proteinligand systems residence time (RT) correlates more strongly with efficacy than binding affinity (1) . Unlike the binding affinity, RT is not a state function; it depends on the height of the free energy barrier separating the bound and unbound states. In order to rationally design ligands for longer RTs we need to understand the (un)binding mechanisma nd what molecular interactions occur along the ligand (un)binding pathway (2) (3) (4) . Previous studies have shown that the translocator protein 18kDa (TSPO) is one such protein where RT is important for predicting efficacy (5) . TSPO is a well-conserved membrane protein, being present all kingdoms including prokaryotes as well as in the outer mitochondrial membrane of eukaryotes (6) . TSPO has five transmembrane α-helices (TM1-5) along with a small helical region in a 20-residue loop connecting TM-1 and TM-2 on the cytosolic side ( Fig. 1A) . While in the membrane, TSPO is largely found in a dimeric state (7) . To date, four different structures have been solved for TSPO structures from both bacterial (7, 8) and mammalian (9, 10) organisms the former by X-Ray crystallography, the latter by NMR. While the structure of TSPO have been solved, its function remains unknown. In humans, TSPO is highly expressed in steroidogenic tissues, leading to the hypothesis that it is involved in the regulation of cholesterol transport across the mitochondrial membrane; indeed, TSPO has been shown to have a high binding affinity for cholesterol (11) . There are other studies linking it to apoptosis (12, 13) and cellular stress regulation in TSPO knockout mice (14, 15) , although evidence for this is mixed (16, 17) . Increased TSPO expression has also been observed in cases of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases (18) . Relatedly, due to its high expression in areas of inflammation TSPO serves as a biomarker for neurodegenerative disease and brain trauma, and radiolabeled ligands such as [H3]-PK-11195, are commonly used in positron emission tomography (PET) scans (19) . PK-11195 (hereafter denoted "PK") is an isoquinoline carboxamide with no known therapeutic effect (17) and a RT of 34 min (5, 20) . Molecular dynamics (MD) simulations have been previously performed using a bound TSPO-PK complex. Researchers recently determined the unbinding pathway of PK from a rat TSPO model generated from the PDB 2MGY structure (21) . To generate unbinding paths they used a combination of random accelerated MD (RAMD) and steered MD (SMD) and determined that PK unbinds into the cytosol through the largely disordered LP1 region. Unfortunately, this starting structure, determined by NMR, was significantly destabilized by the detergent used in the purification (22) (23). Also, the methods used to determine the unbinding pathway (RAMD) have the potential to impart bias on the predicted (un)binding path, as they affect the kinetics of transition between microstates along the path. Another group performed an induced-fit docking of PK using Glide (24) with a homology model to resemble the mammalian (mouse) TSPO structure using the PDB 4UC1 Rhodobacter sphaeroides structure. They simulated the TSPO-PK complex for 700 ns and did not observe significant ligand displacement, which is expected due to the extremely long RT of the TSPO-PK complex.
Here we study the unbinding mechanism for the TSPO-PK complex, using PDB 4UC1 as the TSPO starting structure (7) and using a weighted ensemble algorithm: Resampling of Ensembles by Variation Optimization (REVO) to generate continuous unbinding pathways without perturbing the underlying dynamics (25) . This algorithm performs MD on many trajectories (walkers) in parallel and performs "merg-ing" and "cloning" operations on the walkers to increase sampling in under-explored regions. REVO chooses trajectories for cloning and merging using an objective function that is based on the distances between walkers: outliers, with large distances to other walkers, are chosen for cloning, and other, more central walkers are chosen for merging (more details in SI S1.4). In weighted ensemble algorithms, each walker is assigned a statistical weight, which is divided upon cloning and summed upon merging, allowing for the direct calculation of observables as weighted averages of trajectory properties. REVO has been previously applied to study ligand unbinding on a series of host-guest systems (26) and the trypsinbenzamidine system (25) . We comprehensively studied the TSPO-PK interaction landscape using a set of REVO simulations initialized at six different starting poses (Fig. 1B) . Pose 4RYI copies the PK orientation from the PDB 4RYI structure (8) , and Poses D1-D4 were constructed by docking PK into 4UC1 using Schrödinger Glide (27) . Pose R was determined previously by Xia et al. (28) . by docking PK into an mTSPO structural ensemble made from PDB 2MGY, 4RYI, and 4UC2 struc- tures (7) . All six poses were then used to initialize otherwise identical systems comprised of the TSPO dimer in its 4UC1 structure, a lipid membrane, 0.15 M KCl and solvated with TIP3 waters using CHARMM-GUI (29) (see SI S1.1-S1.3). Each pose was simulated using three independent REVO simulations with 48 walkers each and 1200 cycles of dynamics and resampling, resulting in a total simulation time of 5.18 µs per pose (31.1 µs total). After the MD simulations were completed, all frames were clustered together into a conformational space network (CSN) shown in Fig. 2 , where each node represents a PK pose (see SI S1.7) and the edges reveal which poses interconvert in our simulations. All of the starting poses form a connected network, though pose R is only connected via a couple of low probability edges to the pose 4RYI ensemble (Fig. S2) . The 4RYI pose is similarly connected to pose D4, but is also connected to the other docked poses via the high lipid accessible surface area (LASA) clusters. Unlike in the Bruno et al. study (21) , PK did not dissoci- ate into the solvent via the LP1 region: it instead dissociates into the membrane. The CSN shows that all the poses, besides pose R, connect directly to the unbound states, shown in yellow and orange, where PK is fully dissolved into the lipid membrane. In all of these pathways, PK exits between TM-1 and TM-2. The pose R trajectories show two different pathways that have a moderate LASA -one between TM-1 and TM-2 and another between TM-2 and TM-5 -where PK forms direct interactions with membrane lipids. Given more simulation time, it is probable that these pathways will connect to the unbound states observed in the other poses.
By summing the weights of the unbinding trajectories, we can directly estimate the unbinding rate for each starting pose ( Fig. 3) . Pose D2 had a high unbinding flux and a predicted mean first passage time of unbinding (MFPT) of less than 0.02 s, indicating a clear lack of stability with respect to the other poses. Poses D3 and D4 had predicted MFPTs of 2.6 and 4.1 minutes, respectively, still lower than the experimental measurements; these estimates are likely to continue to decrease with further simulation time. Poses 4RYI and D1 had MFPT estimates near or above the experimental MFPT (28 and 260 min, respectively). No unbinding events were observed for Pose R.
We introduce the coordinate Q ij , which measures the minimum x-y distance from the center of mass of the ligand to the line connecting the centers of mass of helix i and helix j (Fig.  4A ). Negative Q values indicate the ligand is within the helical bundle and positive values indicate the ligand is outside the bundle. This provides a basis to compare between different pathways and a means of obtaining general information about membrane-mediated ligand unbinding pathways. Fig.  4B compares the TSPO-PK interaction energy (E int ) with membrane-PK interaction energy. In the Q 12 pathway (solid lines), PK interacts more closely with the lipid membrane than TSPO after about 5 Å. For the Q 25 pathway (dashed lines) this crossover occurs at 7.5 Å. The difference is due to the orientation of PK along the two pathways: it dissociates with its hydrophobic tail first in the Q 12 pathway and aromatic rings first in the Q 25 pathway (Fig. 4D ).
We also measure E int profiles between PK and individual residues for all residues on TM1, TM2, TM5 and LP1 ( Fig. S4-S7 ). Early in both the Q 12 and Q 25 pathways, PK strongly interacts with aromatic residues Phe46 and Trp50 forming π-π interactions. These aromatic residues with long sidechains follow PK along the unbinding pathway, which is observed by plotting the Q value of individual residues as a function of Q-PK ( Fig. S8 and S9 ). Interestingly, this phenomenon occurs for smaller amino acid sidechains as well: Gly22 and Pro47 both change Q value significantly over the Q 12 pathway, indicating significant distention of the helices during unbinding.
The results of our simulation show that from all six initial PK poses, using the R. sphaeroides TSPO structure, the ligand dissociates into the membrane through the transmembrane helices. However, previous contradictory results (21) used a different starting pose and TSPO structure. One key difference is a salt bridge formed between Asp32 and Arg43 in the R. sphaeroides structure that stabilizes the helix in the LP1 region. This stabilization limits the freedom of motion of the LP1 loop, sterically hindering PK from leaving via the pathway observed by Bruno et al. (21) . Additionally, the Trp50 residue is highly conserved across organisms of several species and kingdoms. It has been shown in our simulations that the aromatic rings of PK form π-π interactions with the Trp50 rings, both in the bound state and along the Q 12 pathway. These stabilizing interactions could lower the barrier to entry for other TSPO ligands such as protoporphyrin-IX and heme, which are also largely aromatic.
PK dissociating into the membrane raises questions about membrane insertion and removal along ligand binding paths.
